Critical mass is reached when 38 of 47 regulators implement FHIR ePI (Voluntary or Required)
Where we stand against each goal
| # | Goal | Indicator | Current | Target | Progress to target |
|---|---|---|---|---|---|
| 1 | Broaden regulatory engagement | Regulators with any identified FHIR ePI activity | 11 / 47 | ≥38 (>80%) |
29% |
| 2 | Move pilots into production | Regulators at Pilot or beyond | 2 / 47 | ≥38 (>80%) |
5% |
| 3 | Reach adoption critical mass
HEADLINE GOAL
|
Regulators at Voluntary or Required | 1 / 47 | ≥38 (>80%) |
3% |
| 4 | Reach conversion critical mass | Implementing regulators with >80% of their labels converted to ePI | Not yet measured (1 regulator implementing) | ≥38 regulators, each with >80% of labels converted | Data not yet collected |
Goals run in sequence: engage, pilot, adopt, then convert. Once a regulator adopts FHIR ePI, the next goal is for more than 80% of its labels to be available as ePI.
Regulatory dates to 2031
▲ Source to be added
▲ Source to be added
Dates are as published by each regulator and may move. EU dates depend on the entry into force of the revised pharmaceutical legislation.
The 47-tile picture
Hover a tile for the regulator name.
Where active regulators sit
Each column is a maturity stage; the goal is to move regulators to the right.
Next promotions to watch
Methodology
- Not identified: No public FHIR ePI activity identified.
- Exploring: Discussion, consultation or early evaluation, proof-of-concept testing, synthetic data.
- Planning: Public commitment, documented, published timelines.
- Pilot: Production use with real data and real submissions; formal and structured; putting systems together, running user acceptance testing, preparing for a production launch.
- Voluntary: FHIR ePI can be used in production voluntarily.
- Required: FHIR ePI is required.
Adoption critical mass. More than 80% of reference regulators implementing FHIR ePI (Voluntary or Required) in their jurisdiction: ≥38 of 47.
Conversion critical mass. After a regulator adopts FHIR ePI, more than 80% of its product labels are converted to ePI.
Denominator. A deduplicated working set of the regulatory authorities that are members or observers of the International Pharmaceutical Regulators Programme (IPRP) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Industry associations, international organizations and regional harmonization initiatives are excluded.
Evidence standard. Each placement should carry an official source, evidence date, scope, last-verified date. “Not identified” means no public FHIR ePI evidence was found in the sources used, not that a regulator is inactive.
